

Sylvain Baruchel-Round 12 (DVL)

Potential for PLK inhibitor in Neuroblastoma and sarcomas

Funded in partnership with the Childhood Cancer Canada and the Coast-to-Coast Against Cancer.

Oral Presentation

Zhang L, Grinstein N., Kaplan D, Baruchel S. Volasertib (BI 6727), a second generation Polo-like kinase 1 (Plk1)inhibitor, is an active agent in preclinical neuroblastoma mouse models. 2012 Advances in Neroblastoma conference. Toronto June 18-21, 2012